BARCLAYS
29.9.2021 09:02:11 CEST | Business Wire | Press release
Barclays today announced the launch of its inaugural Green Structured Notes Programme.
The programme offers institutional and retail investors a differentiated green investment opportunity, with the structured note payoff based on a green index. In addition, the proceeds of the notes are allocated to the financing or re-financing of eligible green activities such as renewable energy, energy efficiency and sustainable transportation loans and contribute to Barclays Net Zero Ambition and providing £100bn of green financing by 2030.
Both the investment and the use of proceeds will be in line with the Sustainable Finance Framework and Green Issuance Framework , and the index is selected in line with the Green Index Selection Principles .
The portfolio of green projects the proceeds will fund will be originated by Barclays Bank PLC in the regular course of business, and will be verified by a third party verification agent. The programme is now open for trading and more information including details on the programme and how to contact Barclays, can be found here.
Commenting on the launch of the programme C.S. Venkatakrishnan, Head of Global Markets and Co-President of BB PLC at Barclays, said:
“We continue to see increased client demand for sustainable investment opportunities and today’s launch of Barclays’ green structured notes programme provides clients with a new and innovative opportunity to access the green market. It’s also a terrific step forward in our innovation journey within Global Markets to offer more compelling and sustainable structured products offerings.”
Sasha Wiggins, Group Head of Public Policy and Corporate Responsibility, said:
“Last year we announced our commitment to align all of our financing to the goals of the Paris Agreement, on the way to achieving our ambition to be a net zero bank by 2050. We also committed to £100bn of green financing by 2030 and this innovative investment offering to our clients is a new and important part of delivering that commitment in order to help accelerate the global transition to a low carbon economy.”
Kathryn McLeland, Group Treasurer, said:
“We are pleased to complement our existing green bond programme with green structured note capabilities, which will expand the diversity of funding sources and is a prime example of how the Power of One Barclays philosophy has been embodied to expand our green product offerings for clients.”
Barclays has a key focus on the impact of our financing and continues to grow its product offering and social and environmental financing activity across the bank. Today’s announcement follows the launch of the Barclays Solactive Climate Change Europe BTI index and Barclays’ intention to support climate-related products and initiatives through Green Bonds issuance . To learn more, click here.
About Barclays:
Barclays is a British universal bank. We are diversified by business, by different types of customers and clients, and by geography. Our businesses include consumer banking and payments operations around the world, as well as a full-service corporate and investment bank.
This communication is provided for informational purposes only and does not, under any circumstances or in any jurisdiction, constitute or form part of an offer to sell, or a solicitation of an offer to buy, any securities issued by Barclays Bank PLC or its affiliates (“Barclays”) nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.
The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “Securities Act”) and have not been offered, directly or indirectly, and will not be offered or sold, directly or indirectly, in or into the United States or to, or for the account or benefit of, any U.S. person (as defined in Regulation S under the Securities Act) absent an applicable exemption from the registration requirements under the Securities Act. Barclays does not intend to register such securities in the United States or to conduct a public offering of securities in the United States or in any other jurisdiction where such offer would be unlawful. Accordingly, no information in this communication or relating to such securities is directed at any person or entity within the United States or at any U.S. person and must not be accessed if you are located in or you are a resident of the United States, and no such communication or information should be released, published or distributed directly or indirectly in or into the United States.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210929005047/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thales Builds Cryptographic Security for the Age of AI and Post-Quantum Computing14.9.2026 09:00:00 CEST | Press release
Thales launches Luna 8, a new hardware security module (HSM) to provide future-ready, quantum resistant security to protect critical data and applications Powered by a Thales designed cryptographic processor, it delivers unparalleled performance, enhanced protection and the flexibility to adapt to new security needs Drawing on decades of cryptographic expertise, Luna 8 combines trusted security with support for emerging technologies, including post quantum cryptography According to the 2026 Thales Data Threat Report, the threat of Harvest Now, Decrypt Later (HNDL) attacks was the top-cited risk, with 59% of organizations reporting that they are prototyping and evaluating post-quantum cryptography (PQC) algorithms to prepare for the quantum era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804748922/en/ ©Thales To help organizations turn this readiness into deployment,Thales, a global leader in advanced technologies, tod
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations14.9.2026 09:00:00 CEST | Press release
Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pill Results from nearly 3,000 patients support potential for next-generation TYK2 inhibitor to redefine oral treatment expectations in psoriasis The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027 Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque psoriasis studies.1-3 Addressing unmet needs in psoriasis treatment “Despite progress in psoriasis care, there remains a need for highly
SWISSto12 and Mitsubishi Electric Corporation Announce Strategic Partnership14.9.2026 09:00:00 CEST | Press release
The Memorandum of Understanding (MoU) and additional contract signal a new phase of collaboration on market development in the Asia Pacific (APAC) region SWISSto12 today announced a memorandum of understanding (MoU) with Mitsubishi Electric Corporation (MELCO) (TOKYO: 6503) to pursue joint opportunities on advanced payloads, radio frequency (RF) products, and market development in Japan and the APAC region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914982179/en/ Masahiko Arai, Executive Officer and Group President, Defense & Space Systems, Mitsubishi Electric, and Dr. Emile de Rijk, Chief Executive Officer, SWISSto12 Joint opportunities will leverage MELCO’s extensive satellite system expertise and integration capabilities together with SWISSto12’s proprietary 3D-printing designs and processes that form the foundation of its next-generation payloads—smaller, lighter, highly performant, yet built in materially shorter
Focused Support Launches Cavok STRIKE to Expand Link-16 Participation Across the Joint Force14.9.2026 07:00:00 CEST | Press release
Extending Link-16 interoperability without platform-level hardware integration Focused Support LLC today announced the launch of Cavok STRIKE, an integrated software capability that expands the Link-16 tactical battlespace picture by enabling additional operational platforms to participate in the Link-16 network. Modern battlefields have increasing numbers of unmanned systems, sensors, and supporting platforms operating throughout the joint battlespace. The rapid proliferation of Group 1, 2, and 3 UAS, including both expendable and recoverable systems, has created a growing need to integrate these assets into the broader tactical network. Many of these platforms provide operationally relevant information but have historically remained outside the Link-16 network due to limitations in size, weight, power, platform integration complexity, or acquisition cost. Cavok STRIKE addresses this gap by enabling platforms to participate in the Link-16 network as non-command-and-control participant
Fujirebio Expands Access to Blood-based Neurology Testing in Brazil with ANVISA Market Authorization for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma14.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted market authorization for the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for use on the fully automated LUMIPULSE® G immunoassay platform in Brazil. “ANVISA authorization of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays marks another important step in our mission to expand access to reliable, clinically meaningful blood-based biomarkers for clinicians and patients worldwide,” said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “By making both neurological biomarker assays available to laboratories on a single, fully automated platform, we are helping support more informed clinical decision-making across a broad range of neurological conditions and throughout the diagnostic pathway.” The Brazilian ANVISA authorizations are based on the already CE marked in vitro diagnostics (IVD) approvals of these two
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom